I

Iovance Biotherapeutics, Inc.

478 employees

Iovance Biotherapeutics is developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Diagnostics
Tumor Infiltrating Lymphocytes (TIL)
Health Care
Novel Cancer Immunotherapies
Autologous Cell Therapy
Medical
Clinical Trials
Immuno Oncology

Date founded

2007

Funding rounds raised

Total raised

$100M

from 2 investors over 2 rounds

I

Iovance Biotherapeutics, Inc. raised $100M on June 3, 2016

Investors: Frazier Healthcare Partners and OrbiMed Advisors

FAQ